PI3K/Akt/mTOR Signaling

GSK-3β inhibitor

GSK3βinhibitor

MTOR inhibitor

PI3K/Akt inhibitor

Class I PI3K inhibitor

PI3Kγ inhibitor,selective and ATP-competitve

Ridaforolimus (Deforolimus, MK-8669) is an orally active and selective Mammalian Target of Rapamycin (mTOR) inhibitor (IC₅₀=0.2nM), Ridaforolimus acts by inhibiting the mTOR signaling pathway, thereby affecting the phosphorylation of downstream effector proteins such as S6 and 4E-BP1.

highly selective p110δ inhibitor

PI3Kγ inhibitor,novel and potent

OSI-027 is a selective small molecule oral inhibitor that can simultaneously inhibit the kinase activities of mTORC1 and mTORC2, with IC 50 values of 22nM and 65nM, respectively.

Potent PI3Kγ inhibitor

WYE-125132 (WYE-132) (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-125132 (WYE-132) (WYE-125132) inhibits mTORC1 and mTORC2.

GSK-3 Inhibitor IX (BIO) is a potent, selective and reversible inhibitor of glycogen synthase kinase-3 (GSK-3) with an IC 50 value of 5nM for GSK-3α/β.

PI3K inhibitor

pan-PI3K inhibitor

GSK2636771 is an orally active selective PI3Kβ inhibitor (K i =0.89nM; IC 50 =5.2nM).

BAY 80-6946 (Copanlisib) (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. BAY 80-6946 (Copanlisib) has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. BAY 80-6946 (Copanlisib) has superior antitumor activity.

GDC-0032 (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

AKT inhibitor

Indirubin is a potent inhibitor of cyclin-dependent kinases (CDKs) (IC 50 : 50-100nmol/L) and glycogen synthase kinase-3beta (GSK-3β) (IC 50 : 5-50nmol/L), with oral administration characteristics.

GSK-3β inhibitor,potent and selective,cell-permeable

Multi-AGC kinase inhibitor,ATP-competitive

GSK2141795 (GSK2141795) is a potent and selective pan-Akt inhibitor with IC50 values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.